Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Contributed by: Business Wire

Logo

Tags

Research

Other Health

General Health

Pharmaceutical

Training

Mental Health

Education

Clinical Trials

Science

Biotechnology

FDA

Health

Other Science

COMP360 Recipients

More Like This

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin